All articles tagged with #amyloid beta
Scientists have discovered two brain receptors, SST1 and SST4, that regulate the breakdown of amyloid beta, a protein linked to Alzheimer's disease. Activating these receptors increases neprilysin levels, reduces amyloid plaques, and improves memory in models, suggesting a potential new, safer, and less expensive treatment approach compared to current antibody therapies.
A study in mice shows that increasing the protein Sox9 reactivates brain cells' cleanup functions, reducing Alzheimer's-like plaques and improving memory, suggesting a potential new treatment approach targeting brain maintenance cells called astrocytes.
A study in mice shows that increasing the protein Sox9 reactivates brain cells' cleaning functions, reducing Alzheimer's-like plaques and improving memory, suggesting a potential new treatment approach targeting brain maintenance cells called astrocytes.
A study published in Nature Medicine found that even modest increases in physical activity, such as walking 3,000-7,500 steps daily, can slow cognitive decline and tau protein buildup in older adults at risk for Alzheimer's, suggesting lifestyle changes may delay disease progression.
Recent research uncovers a harmful interaction between amyloid beta and fibrinogen that forms resistant blood clots, contributing to early signs of Alzheimer's disease by damaging blood vessels and synapses, and suggests targeting this complex could offer new therapeutic avenues.
Scientists have developed a novel nanoparticle-based approach that repairs the blood-brain barrier in mice, leading to rapid clearance of Alzheimer's-related plaques and improved cognitive function, suggesting a potential new direction for treatment research, though human applicability remains uncertain.
Scientists at St. Jude's have discovered that the protein midkine can prevent the formation of toxic amyloid beta clumps associated with Alzheimer's, suggesting potential new avenues for treatment.
Scientists at St. Jude have discovered that the protein midkine prevents the formation of toxic amyloid beta clumps associated with Alzheimer's, opening new avenues for potential treatments by understanding its protective mechanism.
UCSF scientists discovered a receptor called ADGRG1 that enables microglia to effectively clear amyloid beta plaques in the brain, which are associated with Alzheimer's disease. The presence of this receptor correlates with milder symptoms, and its absence leads to plaque buildup and neurodegeneration, offering a promising target for developing new therapies.
A Yale study suggests COVID-19 may cause Alzheimer's-like plaques in the brain and eyes, potentially explaining symptoms like brain fog, with amyloid beta buildup linked to the virus's spike protein and NRP1 receptor, offering new avenues for treatment and diagnosis.
A Yale study suggests that SARS-CoV-2 can induce amyloid beta buildup in retinal tissue, which is associated with Alzheimer's disease, and highlights the potential of targeting NRP1 to prevent neurological complications like brain fog following COVID-19.
Recent research suggests that a protein from the stomach bacteria Helicobacter pylori, traditionally known for causing ulcers, may help prevent the buildup of proteins linked to Alzheimer's disease, offering a potential new therapeutic approach, though it is still in early experimental stages.
Researchers have developed sugar-coated nanomaterials that can trap misfolded amyloid beta proteins, potentially preventing the formation of toxic plaques associated with Alzheimer's disease, offering a promising early intervention approach. Further studies are needed to assess their effectiveness in humans.
Researchers have decoded the structure of amyloid beta fibrils linked to the Arctic mutation, a rare inherited form of Alzheimer's disease, using cryo-electron microscopy and NMR. This mutation leads to the formation of unique cottonwool plaques, which are significantly larger than typical Alzheimer's plaques. Understanding these structures could guide the development of targeted therapies, particularly antibody-based treatments, for specific Alzheimer's subtypes.
A study by researchers from UC Berkeley, Stanford, and UC Irvine suggests that deep sleep may help mitigate memory decline associated with Alzheimer's disease. The research found that older adults with Alzheimer's-related brain changes performed better on memory tests if they had more deep sleep, highlighting sleep as a modifiable risk factor. The study emphasizes the importance of non-rapid eye movement slow wave sleep and suggests lifestyle changes to improve sleep quality, potentially delaying cognitive symptoms of Alzheimer's.